Curasight A/S

Equities

CURAS

DK0061295797

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
10.05 ^DKK	0.00%		+0.50%	-43.38%

Apr. 16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
Apr. 12	Curasight A/S Announces Board Changes	CI

Curasight A/S : presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021

October 15, 2021 at 06:32 am EDT

Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen20 October 2021, 15:10 (CET).

The conference will be a live event with physical presentation. The conference will not be webcasted live, but will be recorded and available on Curasight's web a few days later.

For more information and registration- please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.

https://news.cision.com/curasight/r/curasight-a-s-presents-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen-20-octobe,c3433723

https://mb.cision.com/Main/19744/3433723/1481461.pdf

Latest news about Curasight A/S

Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	Apr. 16	CI
Curasight A/S Announces Board Changes	Apr. 12	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	Feb. 13	CI
Curasight Gears Up for Phase II Study in Prostate Cancer	Dec. 22	CI
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	Dec. 18	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	23-10-18	CI
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	23-09-14	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	23-06-29	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	23-06-07	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	23-05-11	CI
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	23-05-01	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors	22-10-13	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer	22-06-30	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-24	CI
Curasight A/S Expands its Strategy and Strengthen its Position as a Theranostic Company	22-02-23	CI

Chart Curasight A/S

Duration

Period

More charts

Company Profile

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURASIGHT A/S	-43.38%	28.57M
IQVIA HOLDINGS INC.	-1.42%	41.52B
LONZA GROUP AG	+42.15%	39.9B
MODERNA, INC.	+1.97%	38.83B
CELLTRION, INC.	-14.19%	26.05B
ICON PUBLIC LIMITED COMPANY	+1.82%	23.78B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.65B
MEDPACE HOLDINGS, INC.	+21.36%	11.53B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.2B

Other Biotechnology & Medical Research